Every 8-K that Dyadic Intl Inc Del (DYAI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DYAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DYAI filings page.
Dyadic International, Inc. entered into agreements for a capital raise combining a registered direct stock sale and a concurrent private placement of warrants. The company agreed to sell 3,625,000 shares of common stock at $0.795 per share under an effective Form S-3 shelf registration and to issue Common Warrants to purchase 3,625,000 shares at an exercise price of $0.84 per share, priced at $0.005 per warrant. Closing is expected on or about August 14, 2026, subject to customary conditions.
Aggregate gross proceeds are expected to be about $2.9 million, to be used for general corporate purposes including R&D, sales and marketing, administrative expenses, working capital, capital expenditures, and potential acquisitions or strategic transactions. The warrant offering is being conducted as a private placement under Section 4(a)(2) and Rule 506, with a Registration Rights Agreement requiring Dyadic to file a resale registration statement for the warrant shares within 30 days after closing. A placement agent agreement with Aegis Capital Corp. covers the offerings, and Dyadic and key stakeholders are subject to 90-day standstill and lock-up restrictions after the defined Release Date.
Dyadic International reported second-quarter 2026 results, combining growing commercial activity with mounting financial pressure. Total revenue was $961,138 for the quarter ended June 30, 2026, slightly below $966,630 a year earlier, as higher grant revenue of $837,252 offset lower research and development and milestone revenue. Cost of revenue rose to $984,165, driven mainly by CEPI and Gates Foundation grant activity, resulting in a negative gross margin.
Operating expenses shifted, with research and development expenses reduced to $332,621 from $629,379, while general and administrative costs increased to $1,689,863, reflecting rebranding, business development, legal and accounting spending. Loss from operations widened to $2,054,204, and net loss was $2,123,884, or $(0.06) per share, compared with $1,793,774, or $(0.06) per share, a year earlier.
Liquidity and balance sheet indicators weakened. As of June 30, 2026, cash, cash equivalents, restricted cash and investment-grade securities totaled $4,794,798, down from $8,587,289 as of December 31, 2025. Total assets were $6,536,531 against total liabilities of $8,923,775, and stockholders’ equity moved to a deficit of $(2,387,244). The company states management has concluded there is substantial doubt about its ability to continue as a going concern for the 12 months following June 30, 2026, and notes potential dilutive capital raises as a risk. Dyadic also highlights progress in commercial shipments, OEM distribution, precision-fermented dairy partnerships, and global health collaborations using its C1 expression system.
Dyadic International, Inc. reported that Nasdaq confirmed the company has regained compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b). As a result, Dyadic’s common stock will continue to be listed and traded on The Nasdaq Capital Market.
Management characterizes the resolution of the listing matter as providing greater stability and reiterates its focus on executing its business strategy, including developing and commercializing its own products, expanding adoption of its C1 and Dapibus™ protein production platforms, advancing strategic collaborations and pursuing long-term shareholder value.
Dyadic International reported results from its 2026 Annual Meeting of Shareholders. Shareholders elected Class I director Seth J. Herbst, M.D., with 18,121,850 votes for and 1,174,107 withheld, plus 10,313,240 broker non-votes. They approved the board’s authorization to implement a reverse stock split within the ratio range described in the proxy, with 25,419,068 votes for, 3,725,962 against, and 464,167 abstentions. Shareholders also ratified Crowe LLP as independent registered public accounting firm for the year ending December 31, 2026, by 28,623,686 votes for, 517,907 against, and 467,604 abstentions. An advisory vote on executive compensation passed with 18,213,001 votes for, 343,799 against, 739,157 abstentions, and 10,313,240 broker non-votes.
Dyadic International, Inc. reports it has received a Nasdaq notification starting a process that could lead to delisting because its share price has stayed below the $1.00 minimum required by Nasdaq Listing Rule 5450(a)(1), known as the Bid Price Rule.
As of June 17, 2026, Dyadic had not regained compliance or met the $5 million shareholders’ equity level needed for an extension. The notice also cites noncompliance with Nasdaq Listing Rule 5550(b), which requires at least $2.5 million in shareholders’ equity, $35 million in market value of listed securities, or $500,000 of net income from continuing operations.
The company plans to request a hearing before an independent Nasdaq panel, which will temporarily halt any suspension or delisting action. Under Nasdaq rules, the latest possible deadline for Dyadic to regain full compliance is December 15, 2026, but there is no assurance it will succeed or avoid delisting.
Dyadic International furnished a press release highlighting growing interest in its C1 microbial protein production platform amid preparedness efforts for the Bundibugyo Ebola virus outbreak and broader commercial use. The company believes C1 can help rapidly manufacture vaccines and antibodies, moving from gene sequence to purified antigen or monoclonal antibody in approximately 15 days.
Dyadic describes three Ebola-related tracks involving Scripps Research, CEPI-linked proposals, and a monoclonal antibody initiative with Fondazione Biotecnopolo di Siena and the European Vaccines Hub. It also outlines a multi-market strategy for its C1 and Dapibus™ platforms across biopharma, life sciences, food and nutrition, and industrial biotechnology, estimating current addressable market opportunities exceeding $25 billion.
Dyadic International announced a collaboration between Dyadic Applied BioSolutions and researchers at Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including the Andes virus strain associated with Hantavirus Pulmonary Syndrome. The work will assess Dyadic’s microbial fungal-based C1 platform for rapid development, high-productivity fermentation, and large-scale biologic manufacturing aimed at future infectious disease preparedness.
The collaboration builds on Dyadic’s prior Andes virus monoclonal antibody research, its preclinical data showing C1-produced antibodies with binding and neutralization characteristics comparable to mammalian systems, and earlier GMP manufacturing and Phase 1 clinical evaluation using C1. Dyadic notes that this and other funded programs backed by organizations such as the Gates Foundation, CEPI, and European initiatives are pursued through grants, sponsored research, and strategic collaborations, allowing validation of the C1 platform while maintaining a primary commercial focus on non-pharmaceutical protein products and industrial-scale biomanufacturing opportunities.
Dyadic International reported much stronger Q1 2026 results, with total revenue of $1,110,956, up 182.3% from $393,572 a year earlier. Growth was driven by higher research and development revenue tied to the Proliant agreement, increased grant revenue from CEPI and the Gates Foundation, and $220,000 of new license and milestone revenue under the Inzymes agreement.
Total costs and expenses rose to $3,013,649, reflecting higher cost of revenue and general and administrative spending, while research and development expenses declined slightly. Loss from operations narrowed to $1,902,693, and net loss improved to $1,954,683, or $(0.05) per share, compared with $(0.07) per share last year. As of March 31, 2026, Dyadic held $6.6 million in cash, equivalents, restricted cash, and investment-grade securities but reported negative stockholders’ equity of $407,732.
Operationally, the company highlighted multiple commercial milestones, including initial purchase orders for recombinant bovine transferrin, the commercial launch of AlbuFree™ DX recombinant human albumin by Proliant, an expanded collaboration with Fermbox Bio, an OEM distribution agreement with IBT Bioservices, and a development and commercialization agreement with BRIG Bio for animal-free bovine alpha-lactalbumin. Dyadic also continued progressing biopharmaceutical programs supported by the Gates Foundation, CEPI, and Fondazione Biotecnopolo di Siena and is expanding its commercial footprint in Asia and Europe.
Dyadic International, Inc. reported that Nasdaq has notified the company it is not meeting the technical minimum requirements under Nasdaq Listing Rule 5550(b) for continued listing on the Nasdaq Capital Market. The rule requires at least $2.5 million in stockholders’ equity, $35 million in market value of listed securities, or $500,000 of net income from continuing operations.
Dyadic has 45 days, until May 11, 2026, to submit a plan to regain compliance and may receive up to 180 days from March 27, 2026 (to September 23, 2026) to cure the deficiency if Nasdaq accepts the plan. Separately, the company also remains out of compliance with Nasdaq’s $1.00 minimum bid price requirement and has until June 17, 2026 to regain compliance with that rule. Failure to cure either deficiency by the applicable deadline could lead to delisting of Dyadic’s common stock.
Dyadic Applied BioSolutions reported weaker 2025 results while advancing multiple commercial partnerships. Total revenue fell to $3.09 million from $3.50 million, mainly due to lower license and milestone revenue, partly offset by a $1.86 million increase in grant revenue from Gates Foundation and CEPI programs.
Loss from operations widened to $7.19 million, with net loss increasing to $7.36 million, or $(0.23) per share, compared with $5.81 million, or $(0.20) per share, in 2024. Cash, cash equivalents, restricted cash and investment-grade securities were about $8.6 million as of December 31, 2025. The company highlighted commercial launches and agreements across life sciences, food and nutrition, and bio-industrial markets, and scheduled an earnings call at 5:00 p.m. Eastern Time on March 25, 2026.
Dyadic International, Inc. entered into an at-the-market equity offering program that allows it to sell shares of its common stock with an aggregate offering price of up to $4,237,818 through Craig-Hallum Capital Group LLC as sales agent.
Sales can be made from time to time under an existing Form S-3 shelf and a new prospectus supplement, using methods such as ordinary broker transactions, block trades, and negotiated deals at market-related prices. Dyadic is not required to sell any shares and can suspend or terminate the program at any time. Craig-Hallum will receive up to 3.0% of the gross sales price as compensation, and Dyadic will reimburse certain expenses and provide customary indemnification.
Dyadic International, Inc. reported that it received a Nasdaq deficiency notice on December 19, 2025 because its common stock failed to maintain the required minimum bid price of $1 per share for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The notice does not immediately affect trading of the shares on the Nasdaq Capital Market.
The company has 180 calendar days, until June 17, 2026, to regain compliance by having its bid price close at or above $1 per share for at least 10 consecutive business days. If it does not regain compliance by that date, Dyadic may qualify for an additional 180-day grace period if it meets other initial listing standards and notifies Nasdaq of its plan to cure the deficiency. Otherwise, its shares could be subject to delisting, though Dyadic would have the right to appeal. The company states it plans to actively monitor its share price and evaluate options to address the issue.
Dyadic International, Inc. filed an 8-K describing two key updates. First, the company furnished a press release highlighting recent milestone achievements and business developments.
More importantly, Dyadic reports it has regained full compliance with Nasdaq listing standards. Its market value of listed securities was at least $35 million for 10 consecutive business days from September 16 to September 30, 2025, satisfying Nasdaq Listing Rule 5550(b)(2). In addition, its common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days from September 19 to October 2, 2025, restoring compliance with Nasdaq Listing Rule 5550(a)(2) and closing prior deficiency matters.
Dyadic International, Inc. reported that it entered into an amendment to its existing Security Agreement covering its Senior Secured Convertible Promissory Notes due March 8, 2027. The amendment, dated September 15, 2025, was executed with a majority of the current noteholders.
The amendment replaces Schedule A of the Security Agreement to update the list of secured parties. These updates include adding a trust established for the benefit of Dyadic’s CEO, Mark Emalfarb, following his purchase and assignment to him of one of the company’s senior secured convertible notes with a principal amount of $1,000,000.
Dyadic International, Inc. filed a Form 8-K to let investors know it has released its financial results for the quarter ended June 30, 2025. The company distributed these results through a press release dated August 13, 2025.
The press release is included as Exhibit 99.1 and is described as being furnished rather than filed under the securities laws, which affects how it is treated for liability and incorporation into other SEC filings.
Dyadic International, Inc. (Nasdaq: DYAI) received a Nasdaq Listing Qualifications notice on 17-Jul-2025 after its common stock failed to meet the $1.00 minimum bid price for the past 30 consecutive business days, violating Rule 5550(a)(2).
The notice does not immediately affect DYAI’s listing. The company has 180 calendar days—until 13-Jan-2026—to regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive trading days. If the requirement is unmet, Dyadic may qualify for a second 180-day grace period, provided it satisfies all initial listing standards other than bid price and formally notifies Nasdaq of its remediation plan. Failure to cure could result in delisting, with the option to appeal.
Management “intends to actively monitor” share price and explore alternatives to resolve the deficiency. The filing also reminds investors that the company remains out of compliance with the $35 million Market Value of Listed Securities rule (Rule 5550(b)(2)); that separate deficiency must be remedied by 20-Dec-2025. Either unresolved deficiency can independently trigger delisting.
Dyadic International (NASDAQ:DYAI) filed an 8-K disclosing receipt of a Nasdaq Listing Rule 5550(b)(2) deficiency notice for failing to maintain the minimum $35 million Market Value of Listed Securities (MVLS).
The stock has been below the threshold for 30 consecutive business days, activating a 180-day cure period ending December 20, 2025. To regain compliance, DYAI’s MVLS must close at or above $35 million for at least 10 consecutive trading days before the deadline. Failure would prompt a delisting determination, which the company could appeal, though success is not assured.
The notice has no immediate effect on Nasdaq trading but flags heightened liquidity and financing risk. Management says it will monitor MVLS and “evaluate available options,” yet outlines no specific actions. Forward-looking statements reiterate ongoing losses, capital needs, and potential breaches of other listing standards, underscoring uncertainty for shareholders.
Dyadic International, Inc. (NASDAQ: DYAI) filed an 8-K to disclose the final results of its 20 June 2025 Annual Meeting of Shareholders.
- Director election – Class III: Founder & CEO Mark A. Emalfarb was re-elected to serve until the 2028 meeting with 15,946,385 votes FOR (96.0% of votes cast) versus 421,896 WITHHELD and 7,892,709 broker non-votes.
- Auditor ratification: Crowe LLP was confirmed as independent registered public accounting firm for FY-2025 with an overwhelming 24,013,307 FOR (99.0%), 237,523 AGAINST and 10,160 ABSTAIN.
- Say-on-pay (advisory): Compensation of named executive officers received 15,765,072 FOR (95.9%), 522,744 AGAINST, 80,465 ABSTAIN, and 7,892,709 broker non-votes.
- Say-on-pay frequency: Shareholders strongly preferred an annual advisory vote: 15,443,558 votes for 1-year, handily exceeding 716,692 (2-years) and 13,576 (3-years). Abstentions were 194,455.
Based on these results, the Board and its Compensation Committee have resolved that future advisory votes on executive compensation will be held once every year.
No other matters were brought before the meeting, and there were no disclosures of earnings, major transactions or material events beyond the voting outcomes.